Inhibrx (NASDAQ:INBX – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21), Zacks reports. The firm had revenue of $0.10 million during the quarter.
Inhibrx Stock Performance
NASDAQ INBX opened at $14.00 on Wednesday. Inhibrx has a 52 week low of $10.80 and a 52 week high of $35.42. The business has a 50 day moving average price of $13.30 and a 200-day moving average price of $14.66.
Analysts Set New Price Targets
Separately, JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
- Five stocks we like better than Inhibrx
- Ride Out The Recession With These Dividend Kings
- 3 Stocks Returning Billions to Shareholders via Buybacks
- Bank Stocks – Best Bank Stocks to Invest In
- Tesla: 1 Reason to Love It, 1 Reason to Be Cautious
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Stocks That Could Win Big From a 10% Cap on Credit Card Rates
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
